Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 44

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 44
---
 with
our ability to make, use, sell and/or export our products or to use our technologies or product names. Moreover, individuals and groups
that are non-practicing entities, commonly referred to as “patent trolls,” purchase patents and other intellectual property
assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening
letters, notices or “invitations to license,” or may be the subject of claims that our products and business operations infringe
or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation,
divert management’s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make
substantial payments.

If we fail to execute invention assignment agreements with our employees and contractors involved in the development of intellectual property or are unable to protect the confidentiality of our trade secrets, the value of our products and our business and competitive position could be harmed.

In addition to patent protection,
we also rely on protection of copyright, trade secrets, know-how and confidential and proprietary information. We generally enter into
confidentiality and invention assignment agreements with our employees, consultants and third parties upon their commencement of a relationship
with us. However, we may not enter into such agreements with all employees, consultants and third parties who have been involved in the
development of our intellectual property. In addition, these agreements may not provide meaningful protection against the unauthorized
use or disclosure of our trade secrets or other confidential information, and adequate remedies may not exist if unauthorized use or
disclosure were to occur. The exposure of our trade secrets and other proprietary information would impair our competitive advantages
and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to
protect our proprietary rights may allow competitors to copy our products and procedures, which could adversely affect our pricing and
market share. Further, other parties may independently develop substantially equivalent know-how and technology.

<div align='center'>31</div>

In addition to contractual
measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological
security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party
with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee
or consultant from misappropriating our trade secrets and providing them to a competitor